Agile Therapeutics Inc. (NASDAQ:AGRX) was up 1.7% on Wednesday . The stock traded as high as $7.15 and last traded at $7.12, with a volume of 152,533 shares traded. The stock had previously closed at $7.00.

A number of equities research analysts recently commented on the stock. FBR & Co reissued a “buy” rating on shares of Agile Therapeutics in a research report on Friday, June 17th. Cantor Fitzgerald reissued a “buy” rating on shares of Agile Therapeutics in a research report on Tuesday, May 31st. Noble Financial reissued a “buy” rating on shares of Agile Therapeutics in a research report on Tuesday. Finally, Zacks Investment Research cut shares of Agile Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $15.00.

The company’s market capitalization is $200.98 million. The stock has a 50-day moving average price of $7.11 and a 200-day moving average price of $6.61.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings data on Monday, August 8th. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.29). Equities analysts expect that Agile Therapeutics Inc. will post ($1.24) EPS for the current year.

A hedge fund recently raised its stake in Agile Therapeutics stock. Marshall Wace LLP raised its position in shares of Agile Therapeutics Inc. (NASDAQ:AGRX) by 4.9% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 129,769 shares of the specialty pharmaceutical company’s stock after buying an additional 6,099 shares during the period. Marshall Wace LLP owned about 0.58% of Agile Therapeutics worth $1,267,000 as of its most recent SEC filing.

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.